According to a media release this morning from AstraZeneca, the company’s investigational drug zibotentan (also known as ZD4054) was not effective in extending the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) in a randomized, double-blind, placebo-controlled Phase III trial. … READ MORE …
Filed under: Drugs in development | Tagged: atrasentan, castration-resistant, mCRPC, metastatic, ZD4054, zibotentan | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 